Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:04 p.m.

    📋 RHYTHM PHARMACEUTICALS, INC. (RYTM) - Financial Results

    Filing Date: 2022-08-02

    Accepted: 2022-08-02 07:02:38

    Event Type: Financial Results

    Event Details:

    Rhythm Pharmaceuticals Inc (RYTM) Reports Q3 2022 Financial Results Rhythm Pharmaceuticals Inc (RYTM) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 2309
    • Net Income: $8
    • EPS: Not disclosed
    • Cash and equivalents: 113207
      • Biedl Syndrome: ·Today, Rhythm announced that more than 35 physicians have written more than 50 prescriptions for IMCIVREE for patients with BBS in the first six weeks since IMCIVREE was approved by the FDA on June 16, 2022 for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to BBS. ·In July 2022, Rhythm announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending to expand the current indication for IMCIVREE to include the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with genetically confirmed BBS. ·In July 2022, Rhythm announced that the French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) granted post
      • marketing authorization AP1 (autorisation d’accès précoce
      • - early access authorization) for setmelanotide for the treatment of obesity and control of hunger in patients with genetically confirmed BBS. AP1 allows for early access to innovative therapies in France prior to regulatory approval when a positive benefit/risk ratio is recognized and when no other therapeutic alternatives are available. POMC and LEPR Deficiency Obesities: ·In July 2022, Rhythm announced that the National Institute for Health and Care Excellence (NICE) issued guidance recommending IMCIVREE as an option for treating obesity and controlling hunger caused by POMC, PCSK1 or LEPR deficiency in people 6 years of age or older. With this recommendation under the Highly Specialised Technologies (HST) pathway, IMCIVREE will be funded and available for use within 90 days in the National Health Service. ·In June 2022, Rhythm launched IMCIVREE in Germany for patients with POMC, PCSK1 or LEPR deficiency obesity. IMCIVREE is the first precision medicine designed to induce weight loss and control of hunger that has received a lifestyle exemption from the German Federal Joint Committee (G
        • anticipated in the fourth quarter of 2022
        • expected in the second half of 2022
        • expected in the fourth quarter of 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Costs And Expenses Selling General Administrative 15.46K 43.78K $-28.31K -64.67%
    Costs And Expenses Loss From Operations 40.43K 97.79K $-57.35K -58.65%
    Current Assets Prepaid Expenses Other Current Assets 12.03K 12.51K $-478.00 -3.82%
    Current Assets Property Equipment Net 2.56K 2.81K $-254.00 -9.03%
    Current Assets Intangible Assets Net 8.31K 4.66K $3.65K +78.42%
    Current Liabilities Accounts Payable 6.01K 5.74K $275.00 +4.79%
    Revenue 2.31K 274.00 $2.04K +743.80%
    Selling, General & Administrative 22.33K 15.46K $6.86K +44.38%
    Loss from Operations 45.10K 40.43K $4.66K +11.54%
    Interest Income 95.00 21.00 $74.00 +352.38%
    Other Income, Net 95.00 21.00 $74.00 +352.38%
    Net Loss 45.00K 35.39K $9.61K +27.16%
    Prepaid Expenses and Other Current Assets 12.03K 12.51K $-478.00 -3.82%
    Property and Equipment, Net 2.56K 2.81K $-254.00 -9.03%
    Intangible Assets, Net 8.31K 4.66K $3.65K +78.42%
    Accounts Payable 6.01K 5.74K $275.00 +4.79%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Rhythm Pharmaceuticals Inc
    • CIK: 0001649904
    • Ticker Symbol: RYTM
    • Period End Date: 2022-08-02
    • Document Type: 8-K

Search

News categories